Results for basiliksimab translation from Croatian to English

djelatna tvar je basiliksimab.
the active substance is basiliximab.

basiliksimab ne izaziva mijelosupresiju.
basiliximab does not cause myelosuppression.

basiliksimab nije imao utjecaja na ove događaje.
these events were not influenced by basiliximab.

simulect 10 mg prašak i otapalo za otopinu za injekciju ili infuziju basiliksimab
simulect 10 mg powder and solvent for solution for injection or infusion

simulect 10 mg prašak i otapalo za otopinu za injekciju/infuziju basiliksimab
simulect 10 mg powder for solution for injection/infusion basiliximab

s obzirom da je basiliksimab imunoglobulin, ne treba očekivati metaboličke interakcije među lijekovima.
because basiliximab is an immunoglobulin, no metabolic drug-drug interactions are to be expected.

basiliksimab ima potencijalno opasne imunosupresivne učinke na tijek trudnoće i dojenče izloženo basiliksimabu preko majčinog mlijeka.
basiliximab has potentially hazardous immunosuppressive effects with respect to the course of gestation and the suckling neonate exposed to basiliximab in breast milk.

incidencija akutne epizode odbacivanja bila je bitno niža u bolesnika koji su dobivali basiliksimab i trostruki režim imunosupresivne terapije.
the incidence of acute rejection episode was substantially lower in patients receiving basiliximab and a triple drug immunosuppressive regimen.

basiliksimab je korišten istovremeno s ciklosporinom u mikroemulziji i steroidima u nekontroliranoj studiji u 41 pedijatrijskog de novo primatelja bubrežnog presatka.
basiliximab was used concomitantly with ciclosporin for microemulsion and steroids in an uncontrolled study in 41 paediatric de novo renal transplant recipients.

incidencija zloćudnih novotvorina: ukupna incidencija zloćudnih bolesti u pojedinačnim studijama među svim bolesnicima koji su primali basiliksimab i uspoređivane skupine bila je slična.
incidence of malignant neoplasms: the overall incidence of malignancies among all patients in the individual studies was similar between the basiliximab and the comparator treatment groups.

u periodu do 6 mjeseci, gubitak presatka javio se u 6% bolesnika koji su primali basiliksimab i 10% koji su primali placebo.
graft loss occurred in 6% of basiliximab-treated and 10% of placebo-treated patients by 6 months.

incidencija infektivnih epizoda: ukupna incidencija i profil virusnih, bakterijskih i gljivičnih infekcija u bolesnika koji su primali basiliksimab ili placebo u kombinaciji s dvostrukom i trostrukom imunosupresivnom terapijom bila je usporediva između skupina.
incidence of infectious episodes: the overall incidence and profile of viral, bacterial and fungal infections among patients treated with basiliximab or placebo in combination with dual and triple immunosuppressive therapy was comparable between the groups.

dvanaestomjesečna, randomizirana, placebom kontrolirana, dvostruko slijepa, multicentrična studija kojom se ocjenjivao basiliksimab u kombinaciji s ciklosporinom u mikroemulziji, mikofenolat mofetilom i steroidima u pedijatrijskih primatelja bubrežnog presatka.
a 12-month, randomised, placebo-controlled, double-blind, multicentre study investigated basiliximab in combination with ciclosporin for microemulsion, mycophenolate mofetil and steroids in paediatric renal allograft recipients.

basiliksimab je kao indukcijski lijek ispitivan u 4 randomizirane, dvostrukoslijepe, placebo- kontrolirane studije u bolesnika kojima je presađen bubreg u kombinaciji sa sljedećim imunosupresivnim režimima: ciklosporin u mikroemulziji i kortikosteroidi u dvije studije (346 i 380 bolesnika), ciklosporin u mikroemulziji, azatioprin i kortikosteroidi u jednoj studiji (340 bolesnika) te ciklosporin u mikroemulziji, mikofenolat mofetil i kortikosteroidi u drugoj studiji (123 bolesnika).
basiliximab has been tested in four randomised, double-blind, placebo-controlled studies in renal transplant recipients as an induction agent in combination with the following immunosuppressive regimens: ciclosporin for microemulsion and corticosteroids in two studies (346 and 380 patients), ciclosporin for microemulsion, azathioprine and corticosteroids in one study (340 patients), and ciclosporin for microemulsion, mycophenolate mofetil and corticosteroids in another study (123 patients).